Wellumio, a New Zealand-based medical technology company specializing in portable neuroimaging for stroke detection, has raised $7.28 million in a pre-Series A funding round led by Nuance Connected Capital, aimed at advancing clinical milestones and operational capabilities for its Axana device.

Information on the target

Wellumio is a New Zealand-based medical technology company that specializes in developing a portable neuroimaging device known as Axana. This innovative technology is designed for rapid, point-of-care stroke detection, enabling healthcare providers to diagnose strokes quickly and efficiently. Recently, Wellumio successfully raised $7.28 million in the first close of its pre-Series A funding round, which will be utilized to accelerate key clinical milestones and enhance the company's operational capabilities.

The Axana device aims to transform stroke care by facilitating timely diagnosis within the critical 'golden hour'—a crucial period where swift intervention can significantly improve patient outcomes. Despite stroke being one of the leading causes of death and long-term disability worldwide, less than five percent of patients currently receive treatment during this vital timeframe.

Industry overview in the target’s specific country

The healthcare landscape in New Zealand is characterized by a strong emphasis on innovation and technology, particularly in the medical device sector. The country has a robust framework for supporting health technology development, including government ini